GlassScriptPhysician profile
Alan Gasner
NPI 1225006638
$1,927.13
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $230 · 2021: $481 · 2022: $606 · 2023: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $301.73 | 2019-2023 | Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $228.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $219.16 | 2019-2021 | |
| Novo Nordisk INC | $199.04 | 2019-2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $148.68 | 2021-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $105.05 | 2019 | |
| Amgen INC. | $103.42 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $97.15 | 2020 | |
| Dexcom, INC. | $95.88 | 2021-2022 | |
| Pfizer INC. | $66.06 | 2020-2021 | |
| Abbvie INC. | $64.36 | 2021-2023 | |
| Lilly USA, LLC | $52.05 | 2021-2022 | |
| Esperion Therapeutics, INC. | $42.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.57 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.73 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $23.39 | 2021 | |
| Dynavax Technologies Corporation | $22.30 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $22.22 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $20.42 | 2019 | |
| Daiichi Sankyo INC. | $14.39 | 2021 | |
| Grt US Holding, INC. | $14.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.